echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medicines Company News > Shandong pharmaceutical companies show their power!

    Shandong pharmaceutical companies show their power!

    • Last Update: 2021-06-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Medical Network News on May 27th.
    Long-acting Shengbaiyao has just been approved.
    Recently, Shandong New Times Pharmaceuticals has approved three more varieties, including axitinib tablets, lipoic acid injection, and tenofovir fumarate.
    Dipyrifurate tablets.
    Among them, axitinib tablet is the first domestic imitation + first review, and lipoic acid injection is the fifth batch of collected varieties.
     
    New Era Pharmaceuticals has recently been approved for listing
    Source: Meinenet MED2.
    0 Chinese Drug Evaluation Database
     
    Axitinib tablets (Inlyta) is a new generation of renal cancer targeted therapy developed by Pfizer.
    It is mainly used for adult patients with advanced renal cancer who have failed previous cytokine-related treatment regimens.
    It is one of the standard treatment options for advanced renal cancer.
    .
    Shandong New Era's axitinib tablet is the first domestic imitation + first review.
     
    According to data from Meinenet, Inlyta’s global sales in 2020 will be 787 million U.
    S.
    dollars, and its terminal sales in China’s urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) will be close to 300 million yuan, year-on-year An increase of 170.
    16%.
     
    Global sales of Inlyta (unit: million dollars)
    Source: Mynet.
    com's sales database of multinational listed companies
     
    Lipoic acid injection medication for diabetes, for paresthesia and other oxidative stress-induced diabetic peripheral neuropathy caused by disease .
    The original research drug of this product is Austrian Stadt, Germany.
    It has been used for the treatment of diabetic neuropathy in Germany for decades, and some domestic manufacturers also use it as a liver protectant.
     
    Lipoic Acid Injection Over-rated Enterprise
    Source: One-click search on Mi Nei.
    com
     
    Lipoic acid injection is the fifth batch of centralized procurement varieties, and Shandong New Era rushed to obtain admission tickets before the bid opening.
    According to data from Meinenet, the sales of terminal lipoic acid injections in China's public medical institutions will exceed 1 billion yuan in 2020.
    At present, there are 20 lipoic acid injection manufacturers in the domestic market, but only 4 companies have been reviewed, including Yabao Pharmaceutical, Chengdu Better Pharmaceutical, Sichuan Meidakang Huakang Pharmaceutical, and Shandong New Times Pharmaceutical.
     
      Tenofovir disoproxil fumarate tablets are oral nucleoside antiviral drugs developed by Gilead.
    It has the advantages of stronger antiviral efficacy, zero drug resistance, and pregnancy grade B.
    It has been prevented and treated by chronic hepatitis B in various countries.
    The guidelines unanimously recommend first-line drugs for the treatment of chronic hepatitis B infection and human immunodeficiency virus type 1 (HIV-1) infection in adults and children 12 years and older .
    Tenofovir disoproxil fumarate tablets have been included in the first batch of centralized procurement, and currently as many as 22 companies have reviewed it.
     
      Data source: Mi Neiwang database
      Medical Network News on May 27th.
    Long-acting Shengbaiyao has just been approved.
    Recently, Shandong New Times Pharmaceuticals has approved three more varieties, including axitinib tablets, lipoic acid injection, and tenofovir fumarate.
    Dipyrifurate tablets.
    Among them, axitinib tablet is the first domestic imitation + first review, and lipoic acid injection is the fifth batch of collected varieties.
     
      New Era Pharmaceuticals has recently been approved for listing
      Source: Meinenet MED2.
    0 Chinese Drug Evaluation Database
     
      Axitinib tablets (Inlyta) is a new generation of renal cancer targeted therapy developed by Pfizer.
    It is mainly used for adult patients with advanced renal cancer who have failed previous cytokine-related treatment regimens.
    It is one of the standard treatment options for advanced renal cancer.
    .
    Shandong New Era's axitinib tablet is the first domestic imitation + first review.
     
      According to data from Meinenet, Inlyta’s global sales in 2020 will be 787 million U.
    S.
    dollars, and its terminal sales in China’s urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) will be close to 300 million yuan, year-on-year An increase of 170.
    16%.
     
      Global sales of Inlyta (unit: million dollars)
      Source: Mynet.
    com's sales database of multinational listed companies
     
      Lipoic acid injection medication for diabetes, for paresthesia and other oxidative stress-induced diabetic peripheral neuropathy caused by disease .
    The original research drug of this product is Austrian Stadt, Germany.
    It has been used for the treatment of diabetic neuropathy in Germany for decades, and some domestic manufacturers also use it as a liver protectant.
     
      Lipoic Acid Injection Over-rated Enterprise
      Source: One-click search on Mi Nei.
    com
     
      Lipoic acid injection is the fifth batch of centralized procurement varieties, and Shandong New Era rushed to obtain admission tickets before the bid opening.
    According to data from Meinenet, the sales of terminal lipoic acid injections in China's public medical institutions will exceed 1 billion yuan in 2020.
    At present, there are 20 lipoic acid injection manufacturers in the domestic market, but only 4 companies have been reviewed, including Yabao Pharmaceutical, Chengdu Better Pharmaceutical, Sichuan Meidakang Huakang Pharmaceutical, and Shandong New Times Pharmaceutical.
     
      Tenofovir disoproxil fumarate tablets are oral nucleoside antiviral drugs developed by Gilead.
    It has the advantages of stronger antiviral efficacy, zero drug resistance, and pregnancy grade B.
    It has been prevented and treated by chronic hepatitis B in various countries.
    The guidelines unanimously recommend first-line drugs for the treatment of chronic hepatitis B infection and human immunodeficiency virus type 1 (HIV-1) infection in adults and children 12 years and older .
    Tenofovir disoproxil fumarate tablets have been included in the first batch of centralized procurement, and currently as many as 22 companies have reviewed it.
     
      Data source: Mi Neiwang database
      Medical Network News on May 27th.
    Long-acting Shengbaiyao has just been approved.
    Recently, Shandong New Times Pharmaceuticals has approved three more varieties, including axitinib tablets, lipoic acid injection, and tenofovir fumarate.
    Dipyrifurate tablets.
    Among them, axitinib tablet is the first domestic imitation + first review, and lipoic acid injection is the fifth batch of collected varieties.
     
      New Era Pharmaceuticals has recently been approved for listing
      Source: Meinenet MED2.
    0 Chinese Drug Evaluation Database
     
      Axitinib tablets (Inlyta) is a new generation of renal cancer targeted therapy developed by Pfizer.
    It is mainly used for adult patients with advanced renal cancer who have failed previous cytokine-related treatment regimens.
    It is one of the standard treatment options for advanced renal cancer.
    .
    Shandong New Era's axitinib tablet is the first domestic imitation + first review.
    Standard Standard Standard
     
      According to data from Meinenet, Inlyta’s global sales in 2020 will be 787 million U.
    S.
    dollars, and its terminal sales in China’s urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) will be close to 300 million yuan, year-on-year An increase of 170.
    16%.
    Hospital hospital hospital
     
      Global sales of Inlyta (unit: million dollars)
      Source: Mynet.
    com's sales database of multinational listed companies
     
      Lipoic acid injection medication for diabetes, for paresthesia and other oxidative stress-induced diabetic peripheral neuropathy caused by disease .
    The original research drug of this product is Austrian Stadt, Germany.
    It has been used for the treatment of diabetic neuropathy in Germany for decades, and some domestic manufacturers also use it as a liver protectant.
    Disease disease disease
     
      Lipoic Acid Injection Over-rated Enterprise
     Enterprise business enterprise
      Source: One-click search on Mi Nei.
    com
     
      Lipoic acid injection is the fifth batch of centralized procurement varieties, and Shandong New Era rushed to obtain admission tickets before the bid opening.
    According to data from Meinenet, the sales of terminal lipoic acid injections in China's public medical institutions will exceed 1 billion yuan in 2020.
    At present, there are 20 lipoic acid injection manufacturers in the domestic market, but only 4 companies have been reviewed, including Yabao Pharmaceutical, Chengdu Better Pharmaceutical, Sichuan Meidakang Huakang Pharmaceutical, and Shandong New Times Pharmaceutical.
     
      Tenofovir disoproxil fumarate tablets are oral nucleoside antiviral drugs developed by Gilead.
    It has the advantages of stronger antiviral efficacy, zero drug resistance, and pregnancy grade B.
    It has been prevented and treated by chronic hepatitis B in various countries.
    The guidelines unanimously recommend first-line drugs for the treatment of chronic hepatitis B infection and human immunodeficiency virus type 1 (HIV-1) infection in adults and children 12 years and older .
    Tenofovir disoproxil fumarate tablets have been included in the first batch of centralized procurement, and currently as many as 22 companies have reviewed it.
    Child, child, kid
     
      Data source: Mi Neiwang database
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.